A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
Summary: Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitate further advancements through pre-clinical in viv...
Similar Items
-
Gene expression profiling of melanoma cells – searching the haystack
by: Herlyn Meenhard, et al.
Published: (2005-01-01) -
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines
by: Bradley Garman, et al.
Published: (2017-11-01) -
Functional profiling of live melanoma samples using a novel automated platform.
by: Adam Schayowitz, et al.
Published: (2012-01-01) -
Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
by: Jessie Villanueva, et al.
Published: (2013-09-01) -
Oncogenic BRAF-Mediated Melanoma Cell Invasion
by: Hezhe Lu, et al.
Published: (2016-05-01)